肺癌化疗所致血小板减少症二级预防方案中重组人血小板生成素使用频次的优化  

Frequency optimization of recombinant human thrombopoietin in secondary prevention of chemotherapy-induced thrombocytopenia in the patients with lung cancer

作　　者：刘丹娜[1] 陈露[1] 苏田丽 吴通 赵晓丽 孔天东[2] LIU Danna;CHEN Lu;SU Tianli;WU Tong;ZHAO Xiaoli;KONG Tiandong(Department of Clinical Pharmacy,Cancer Hospital of Henan University/the Third People’s Hospital of Zhengzhou,Zhengzhou 450000,China;Department of Oncology,Cancer Hospital of Henan University/the Third People’s Hospital of Zhengzhou,Zhengzhou 450000,China)

机构地区：[1]河南大学肿瘤医院/郑州市第三人民医院临床药学室,郑州450000 [2]河南大学肿瘤医院/郑州市第三人民医院肿瘤内科,郑州450000

出　　处：《药学服务与研究》2022年第1期29-33,共5页Pharmaceutical Care and Research

基　　金：河南省医学科技攻关计划项目(2018020746);第二届三生TCP中青年科研基金(20180048)。

摘　　要：目的:探讨隔日或每日使用重组人血小板生成素(recombinant human thrombopoietin,rhTPO)在肺癌化疗所致血小板减少症(chemotherapy-induced thrombocytopenia,CIT)二级预防中的疗效及安全性。方法:以60例符合条件的肺癌患者为观察组,隔日使用rhTPO 300 U/(kg·d)。回顾性收集既往每日使用rhTPO 300 U/(kg·d)进行CIT二级预防的57例肺癌患者为对照组。观察两组患者的血小板变化值、至下周期化疗前血小板回升至正常值患者比例以及安全性。结果:在使用rhTPO二级预防CIT的第3、5、7、10、12天,两组患者每天血小板变化值无显著差异(P>0.05)。对照组和观察组血小板变化幅度最大值分别为(120±79)×10^(9)/L和(139±75)×10^(9)/L,差异无统计学意义(P>0.05)。至下周期化疗前血小板回升至正常值患者比例,对照组和观察组分别为80.70%和71.60%,差异无统计学意义(P>0.05)。两组患者的安全性良好,不良反应发生率无统计学差异。结论:隔日或每日使用相同剂量rhTPO进行CIT二级预防,疗效及安全性无显著差异,但隔日使用rhTPO明显降低了医疗费用,提高了患者的治疗依从性。Objective:To investigate the efficacy and safety of recombinant human thrombopoietin(rhTPO)used every day or every other day in secondary prevention of chemotherapy-induced thrombocytopenia(CIT)in the patients with lung cancer.Methods:Totally,60 lung cancer patients conformed with the selection criteria were designated as the observation group and were treated with rhTPO 300 U/(kg·d)every other day.Retrospectively,57 lung cancer patients treated daily with rhTPO 300 U/(kg·d)for secondary prevention of CIT were designated as the control group.The changes of platelets,the proportion of the patients whose platelets recovered to normal value before next cycle of chemotherapy and safety were closely observed in the process.Results:No significant differences in the changes of platelet were noted on the 3rd,5th,7th,10th and 12th day,in secondary prevention of chemotherapy-induced thrombocytopenia(CIT)by using rhTPO to prevent CIT,when comparisons were made between the patients of the 2 groups(P>0.05).The maximum values of platelet changes in the prevention cycle in the control group and the observation group were respectively(120±79)×10^(9)/L and(139±75)×10^(9)/L,without statistical significance(P>0.05).Before next cycle of chemotherapy,the proportions of platelets returning to normal value were respectively 80.70%and 71.60%in the observation group and in the control group,also without statistical significance(P>0.05).Good safety was shown in both groups,and there was no statistical significance in the rate of adverse reactions,when comparisons were made between the patients of the 2 groups.Conclusion:In secondary prevention of CIT with rhTPO,there are no significant differences in both efficacy and safety,when same dosages of rhTPO were applied either every day or every other day.However,medical cost could obviously be reduced when rhTPO is used every other day,and at the same time improves treatment compliance of patients.

关 键 词：重组人血小板生成素 化疗所致血小板减少症 肺癌 二级预防 

分 类 号：R973[医药卫生—药品] R969.3[医药卫生—药学]